Abstract:The development of innovative targeted therapeutic approaches are expected to surpass the efficacy of current forms of treatments and cause less damage to healthy cells surrounding the tumor site. Since the first development of targeting agents from hybridoma's, monoclonal antibodies (mAbs) have been employed to inhibit tumor growth and proliferation directly or to deliver effector molecules to tumor cells. However, the full potential of such a delivery strategy is hampered by the size of mAbs, which will obstruct the targeted delivery system to access the tumor tissue. By serendipity, a new kind of functional homodimeric antibody format was discovered in camelidae, known as heavy-chain antibodies (HCAbs). The cloning of the variable domain of HCAbs produces an attractive minimal-sized alternative for mAbs, referred to as VHH or nanobodies (Nbs). Apart from their dimensions in the single digit nanometer range, the unique characteristics of Nbs combine a high stability and solubility, low immunogenicity and excellent affinity and specificity against all possible targets including tumor markers. This stimulated the development of tumor-targeted therapeutic strategies. Some autonomous Nbs have been shown to act as antagonistic drugs, but more importantly, the targeting capacity of Nbs has been exploited to create drug delivery systems. Obviously, Nb-based targeted cancer therapy is mainly focused toward extracellular tumor markers, since the membrane barrier prevents antibodies to reach the most promising intracellular tumor markers. Potential strategies, such as lentiviral vectors and bacterial type 3 secretion system, are proposed to deliver target-specific Nbs into tumor cells and to block tumor markers intracellularly. Simultaneously, Nbs have also been employed for <i>in vivo</i> molecular imaging to diagnose diseased tissues and to monitor the treatment effects. Here, we review the state of the art and focus on recent developments with Nbs as targeting moieties for drug delivery systems in cancer therapy and cancer imaging.

Research Progress of Nanobodies in Diagnosis and Therapy of Tumor

[Application of nanobody in cancer treatment].

Single domain antibody: Development and application in biotechnology and biopharma

Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics

Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies

Application Progress of the Single Domain Antibody in Medicine

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy

Nanobody: a promising toolkit for molecular imaging and disease therapy

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics

Nanobodies: a promising approach to treatment of viral diseases

Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management

Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years

Nanobodies: natural single-domain antibodies.

Nanobody Conjugates for Targeted Cancer Therapy and Imaging

Single-domain antibodies as therapeutics for solid tumor treatment

Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies

Nanobodies: a new potential for prostate cancer treatment

Immunogenicity Risk Profile of Nanobodies

Nanobody-based heavy chain antibodies and chimeric antibodies